Characterization and determination of the complex between prostate-specific antigen and α1-protease inhibitor in benign and malignant prostatic diseases

REFERENCES

• Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159–63.
   PubMedGoogle Scholar
• Wang M, Loor RM, Li S-L, Chu T. Physico-chemical characterization of prostate antigen purified from human prostate gland and seminal plasma. IRCS J Med Sci 1983; 11: 327–8.
   Google Scholar
• Watt KW, Lee PJM, Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986; 83: 3166–70.
   Google Scholar
• Qiu SD, Young CY, Bilhartz DL, Prescott JL, Farrow GM, He WW, Tindall DJ. In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol 1990; 144: 1550–6.
   Google Scholar
• Pollen JJ, Dreilinger A. Immunohistochemical identification of prostatic acid phosphatase and prostate specific antigen in female periurethral glands. Urology 1984; 23: 303–4.
   PubMed Web of Science ®Google Scholar
• Yu H, Diamandis EP, Sutherland DJ. Immunor-eactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994; 27: 75–9.
   Google Scholar
• Akiyama K, Nakamura T, Iwanaga S, Hara M. The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein. FEBS Lett 1987; 225: 168–72.
   PubMed Web of Science ®Google Scholar
• Schaller J, Akiyama K, Tsuda R, Hara M, Marti T, Rickli EE. Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma. Eur J Biochem 1987; 170: 111–20.
   PubMedGoogle Scholar
• Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reac-tions with extracellular serine proteinase inhibi-tors. Eur J Biochem 1990; 194: 755–63.
   Google Scholar
• Lilja H, Abrahamsson PA, Lundwall A. Semeno-gelin., the predominant protein in human semen.: Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem 1989; 264: 1894— 900.
   Google Scholar
• Espana F, Gilabert J, Estelles A, Romeu A, Aznar J, Cabo A. Functionally active protein C inhibitor/ plasminogen activator inhibitor-3 (PCl/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res 1991; 64: 309–20.
   PubMed Web of Science ®Google Scholar
• Christensson A, Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 1994; 220: 45–53.
   PubMedGoogle Scholar
• Leinonen J, Zhang WM, Stenman UH. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996; 155: 1099–103.
   Google Scholar
• Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995; 41: 1567–73.
   Google Scholar
• Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–16.
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, et al. Measure-ment of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–61.
   PubMed Web of Science ®Google Scholar
• Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan 0. A complex between prostate-specific antigen and alpha-l-antichymo-trypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222–6.
   Google Scholar
• Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson 0, Pettersson K, Lovgren T. Prostate-specific antigen in serum occurs predo-minantly in complex with alpha-l-antichymo-tryp sin. Clin Chem 1991; 37: 1618–25.
   Google Scholar
• Leinonen J, Lovgren T, Vomanen T, Stenman UH. Double-label time-resolved immunofluoro-metric assay of prostate-specific antigen and of its complex with alpha-l-antichymotrypsin. Clin Chem 1993; 39: 2098–103.
   PubMed Web of Science ®Google Scholar
• Christensson A, Bjork T, Nilsson 0, Dahlen U, Matikainen MT, Cockett AT, Abrahamsson PA, et al. Serum prostate specific antigen complexed to alpha-l-antichymotrypsin as an indicator of pros-tate cancer. J Urol 1993; 150: 100–5.
   Google Scholar
• Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL. Multiple forms of prostate-specific antigen in serum: differences in immunor-ecognition by monoclonal and polyclonal assays. Clin Chem 1993; 39: 2483–91.
   Google Scholar
• Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Rannikko S, Stenman UH. Char-acterization and immunological determination of the complex between prostate-specific antigen and alpha-2-macroglobulin. Clin Chem 1998; 44: 2471–9.
   Google Scholar
• Zhang WM, Finne P, Leinonen J, Salo J, Stenman UH. Determination of prostate-specific antigen complexed with alpha-2-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology 2000; 56: 267–72.
   Google Scholar
• Berninger RW. Protease inhibitors of human plasma. Alpha-l-antitrypsin. J Med 1985; 16: 23–99.
   Google Scholar
• Storiko K. Normal values for 23 different human plasma proteins determined by single radial immunodiffusion. Blut 1968; 16: 200–8.
   PubMedGoogle Scholar
• Carrell RW, Jeppsson JO, Laurell CB, Brennan SO, Owen MC, Vaughan L, Boswell DR. Structure and variation of human alpha-l-anti-trypsin. Nature 1982; 298: 329–34.
   Google Scholar
• Morii M, Odani S, Koide T, Ikenaka T. Human alpha-l-antitrypsin J Biochem 1978; 83: 269–77.
   Google Scholar
• Morii M, Odani S, Ikenaka T. Characterization of a peptide released during the reaction of human at-antitrypsin and bovine a-chymotrypsin. J Bio-chem 1979; 86: 915–21.
   Google Scholar
• Vercaigne-Marko D, Davril M, LaMe A, Hayem A. Interaction of human alpha-l-proteinase inhi-bitor with human leukocyte cathepsin G. Biol Chem Hoppe Seyler 1985; 366: 655–61.
   PubMed Web of Science ®Google Scholar
• Hoidal JR, Niewoehner DE. Pathogenesis of emphysema. Chest 1983; 83: 679–85.
   PubMed Web of Science ®Google Scholar
• Zhang WM, Leinonen J, Kalkkinen N, Stenman UH. Prostate-specific antigen forms a complex with and cleaves alpha-1-protease inhibitor in vitro. Prostate 1997; 33: 87–96.
   PubMed Web of Science ®Google Scholar
• Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Stenman UH. Measurement of the complex between prostate-specific antigen and alpha-1-protease inhibitor in serum. Clin Chem 1999; 45: 814–21.
   Google Scholar
• Martodam RR, Liener IE. The interaction of alpha-l-antitrypsin with trypsin, chymotrypsin and human leukocyte elastase as revealed by end group analysis. Biochim Biophys Acta 1981; 667: 328–40.
   PubMed Web of Science ®Google Scholar
• Johnson D, Travis J. Structural evidence for methionine at the reactive site of human alpha-1-proteinase inhibitor. J Biol Chem 1978; 253: 7142–4.
   PubMed Web of Science ®Google Scholar
• Travis J, Guzdek A, Potempa J, Watorek W. Serpins: structure and mechanism of action. Biol Chem Hoppe Seyler 1990; 371: 3–11.
   PubMed Web of Science ®Google Scholar
• Beatty K, Travis J, Bieth J. The effect of alpha-2-macroglobulin on the interaction of alpha-1-proteinase inhibitor with porcine trypsin. Biochim Biophys Acta 1982; 704: 221–6.
   Google Scholar
• Leinonen J, Zhang WM, Paus E, Stenman UH. Reactivity of 77 antibodies to prostate specific antibody with isoenzymes and complexes of PSA. Tumour Biol 1999; 20 Suppl. 1: 28–34.
   Google Scholar
• Piironen T, Pettersson K, Suonpaa M, Stenman UH, Oesterling JE, Lovgren T, Lilja H. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha-l-antichymotrypsin in blood samples. Urol-ogy 1996; 48: 81–7.
   Google Scholar
• Pettersson K, Piironen T, Seppala M, Liukkonen L, Christensson A, Matikainen MT, Suonpaa M, et al. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and devel-opment of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha-l-antichymotrypsin complex. Clin Chem 1995; 41: 1480–8.
   PubMed Web of Science ®Google Scholar
• Graves HC. The effect of surface charge on non-specific binding of rabbit immunoglobulin G in solid-phase immunoassays. J Immunol Methods 1988; 111: 157–66.
   Google Scholar
• Graves HC. Noise control in solid-phase immu-noassays by use of a matrix coat. J Immunol Methods 1988; 111: 167–78.
   Google Scholar
• Finne P, Zhang W-M, Auvinen A, Leinonen J, Määttänen L, Rannikko S, Tammela TLJ, et al. Use of the complex between prostate-specific antigen and al-protease inhibitor in screening for prostate cancer. J Urol 2000; 164: 1956–60.
   Google Scholar
• Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multi-center clinical trial of 6,630 men. J Urol 1994; 151: 1283 — 90.
   Google Scholar
• Schroder FH, Bangma CH. The European Ran-domized Study of Screening for Prostate Cancer (ERSPC). Br J Urol 1997; 79: 68–71.
   Google Scholar
• Maattanen L, Auvinen A, Stenman UH, Rannikko S, Tammela T, Aro J, Juusela H, et al. European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer 1999; 79: 1210–4.
   PubMed Web of Science ®Google Scholar